AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11944733
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment groups (G1 and G2)
Trial: 9598253
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide inhalation (5 and 10 ppm for two hours)
Trial: 9598253
Drug: Prone positioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prone positioning + Almitrine (16 mg.kg-1.min-1)
Trial: 9598253
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no further inhalation after initial NO)
Trial: 29570044
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase standard dose of 0.9 mg/kg, up to a maximum of 90 mg, plus oral aspirin placebo
Trial: 29570044
Drug: Intravenous alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alteplase placebo plus active oral aspirin dose of 325 mg
Trial: 24002278
Drug: FDC-based strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC-based strategy (n=1002) containing either (1) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 50 mg atenolol or (2) 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide
Trial: 21558462
Drug: Progesterone (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (90 mg vaginally) from 24 to 34 weeks of pregnancy
Trial: 19850249
Drug: Combination-facilitated PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination-facilitated PCI (abciximab plus half-dose reteplase)
Trial: 18499565
Drug: Primary PCI
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary PCI (abciximab administered immediately before the procedure)
Trial: 18499565
Drug: Combination-facilitated PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination-facilitated PCI
Trial: 16575661
Drug: Vacuum-assisted closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-assisted closure (V.A.C.)-therapy (group B)
Trial: 8931286
Drug: Demand valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand valve system with oral-nasal mask
Trial: 24684977
Drug: Sleep medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep medication (melatonin 14%, clonidine 9%)
Trial: 15793183
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg, twice daily)
Trial: 9435408
Drug: Raloxifene (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (400 mg) for 5 days in any phase of the menstrual cycle
Trial: 9435408
Drug: Raloxifene (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (100 or 200 mg) for 28 days starting on day 3 of the cycle
Trial: 18533940
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine (13vPnC)
Trial: 18533940
Drug: 23-valent plain
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent plain polysaccharide pneumococcal vaccine (23vPn)
Trial: 1750603
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg epidural diamorphine
Trial: 1750603
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg epidural diamorphine
Trial: 1750603
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg epidural diamorphine with adrenaline 1/200,000
Trial: 1750603
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg epidural diamorphine with adrenaline 1/200,000
Trial: 1750603
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg epidural diamorphine with adrenaline vs 2.5 mg with adrenaline
Trial: 30120138
Drug: Fremanezumab 225
RxNorm normalized name: FREMANEZUMAB 225 mg in 1.5 mL SUBCUTANEOUS INJECTION [AJOVY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fremanezumab 225 mg
Trial: 30120138
Drug: Fremanezumab 675
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab 675 mg
Trial: 28768076
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (HOPPS study)
Trial: 22353604
Drug: i.v. ferric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ferric carboxymaltose and subcutaneous erythropoietin (EPOFE arm)
Trial: 22353604
Drug: i.v. placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. placebo and subcutaneous placebo (PLACEBO arm)
Trial: 7635993
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day and Methadone 65-80 mg
Trial: 26508834
Drug: Urinary kallidinogenase
RxNorm normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary kallidinogenase (UK) + conventional treatment
Trial: 12753341
Drug: IFN-alpha2b plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2b plus ribavirin (600 mg/day) for 24 weeks and IFN-alpha2b alone for the next 24 weeks (R2: 48 patients)
Trial: 12753341
Drug: Ribavirin dose
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin dose below 10.6 mg/kg/day
Trial: 12753341
Drug: Ribavirin dose
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin dose over 10.6 mg/kg/day
Trial: 9187104
Drug: Vorozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorozole (2.5 mg once daily for 7 days)
Trial: 2880069
Drug: BN 52063
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN 52063 (80 mg)
Trial: 2880069
Drug: BN 52063
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN 52063 (120 mg)
Trial: 2880069
Drug: BN 52063
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN 52063 (80 mg and 120 mg)
Trial: 30597865
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (PROHIGH: 2.9 g·kg−1·d−1)
Trial: 30597865
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein diet (PROMOD: 1.8 g·kg−1·d−1)
Trial: 26789541
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg silodosin once daily for 4 weeks
Trial: 26789541
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg tamsulosin once daily for 4 weeks
Trial: 1314260
Drug: Pindolol 15
RxNorm normalized name: pindolol 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 15 mg/day
Trial: 23928836
Drug: Doxycycline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (20 mg orally, twice a day for at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days)
Trial: 10867543
Drug: HDhep (heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDhep (heparin anticoagulation)
Trial: 9327192
Drug: Sulodexide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide (250 lipoproteinlipase releasing units, two capsules twice daily for 176 days on average)
Trial: 9327192
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg tablets, one tablet three times a day for 180 days on average)
Trial: 3710287
Drug: Vaginal therapy
RxNorm normalized name: Monistat Simple Therapy Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal therapy with 500 mg metronidazole once a day for 7 days
Trial: 3710287
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy with 400 mg metronidazole twice daily for 7 days
Trial: 3710287
Drug: Vaginal therapy
RxNorm normalized name: Monistat Simple Therapy Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal therapy
Trial: 29684433
Drug: Titrated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oxygen (initially 2 L/min, later adjusted to 4 L/min if tolerated)
Trial: 29684433
Drug: Control oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oxygen (>10 L/min)
Trial: 27821114
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (9,000 lux)
Trial: 27821114
Drug: Dim red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red light therapy (100 lux)
Trial: 20430138
Drug: Dietary education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary education using Food Standards Australia and New Zealand's low-salt guideline of 120 mg sodium/100 g food
Trial: 12966258
Drug: 0.5mg/kg ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg/kg ketamine administered epidurally (Kepi group)
Trial: 12966258
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine administered intravenously (Kiv group)
Trial: 12966258
Drug: 10ml normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml normal saline administered epidurally (Ctr group)
Trial: 8772558
Drug: Alendronate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (40 mg daily for 6 months)
Trial: 8772558
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg daily for 6 months)
Trial: 1334248
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g daily of oatbran
Trial: 6397334
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pivmecillinam plus 250 mg pivampicillin twice daily for 5 days
Trial: 6397334
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg amoxycillin plus 125 mg clavulanate 3-times daily for 5 days
Trial: 19458488
Drug: VCL‐AB01 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCL‐AB01 (0.2 mg)
Trial: 19458488
Drug: VCL‐AB01 (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCL‐AB01 (0.6 mg)
Trial: 19458488
Drug: VCL‐AB01 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCL‐AB01 (2 mg)
Trial: 19458488
Drug: VCL‐AB01 (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCL‐AB01 (0.6 mg) in nonhuman primates
Trial: 11747385
Drug: Prophylactic use
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic use of beta-adrenergic blockers
Trial: 2905252
Drug: Roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine acetate 150 mg post cenam nocte (PCN)
Trial: 2905252
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg post cenam nocte (PCN)
Trial: 2905252
Drug: Roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine acetate 300 mg post cenam nocte (PCN)
Trial: 24481570
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean final dose 14.4 mg/day)
Trial: 19577277
Drug: Intraperitoneal (IP)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) chemotherapy (at least 5 cycles)
Trial: 30873623
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic treatment
Trial: 11222822
Drug: Various drugs
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various drugs used for disease control during pregnancy
Trial: 9221559
Drug: Peroral chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroral chemotherapy (Hydroxyurea or Busulphan)
Trial: 2139409
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d Gallopamil (group 1)
Trial: 2139409
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d Metoprolol (group 2)
Trial: 2139409
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Atenolol and 20 mg Nifedipine daily (group 3)
Trial: 2139409
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Acebutolol plus 20 mg Nifedipine daily (group 4)
Trial: 2139409
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Atenolol plus 10 mg Enalapril daily (group 5)
Trial: 7247639
Drug: Combined pharmacotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pharmacotherapy and behavior therapy
Trial: 2613427
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy alone
Trial: 31567411
Drug: Oral fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fosfomycin monotherapy for uncomplicated UTI and bacterial prostatitis
Trial: 31567411
Drug: Intravenous fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosfomycin in combination with other agents
Trial: 26775373
Drug: Tramadol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (75 mg/day)
Trial: 26775373
Drug: Tramadol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol + Gabapentin (75 mg/day tramadol + 900 mg/day gabapentin)
Trial: 25881758
Drug: Control (waiting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (waiting list under drug treatment)
Trial: 24311316
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii 500 mg/day + AB
Trial: 18647982
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg adjustable to 100 mg before sexual activity)
Trial: 14740953
Drug: Monovalent live‐attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent live‐attenuated dengue virus (DENV) vaccine candidates
Trial: 10674459
Drug: Gadodiamide injection
RxNorm normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadodiamide injection at a dosage of 0.1 mmol/kg body weight
Trial: 9846855
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A (200,000 IU; 100,000 IU if aged <12 mo)
Trial: 9846855
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin A (5000 IU/d until discharge)
Trial: 7905256
Drug: Adjunctive imipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive imipramine hydrochloride (mean, 233 +/- 72 mg/d)
Trial: 2645914
Drug: Nicardipine 30
RxNorm normalized name: niCARdipine 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 30 mg tid
Trial: 2645914
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg tid
Trial: 2645914
Drug: Nicardipine 30
RxNorm normalized name: niCARdipine 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 30 mg tid and Propranolol 40 mg tid
Trial: 1097295
Drug: Azathioprine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (1.5 mg per kg)
Trial: 31027246
Drug: Caffeinated gel
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated gel (300 mg of caffeine)
Trial: 28974184
Drug: Minimal supportive
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal supportive treatment/waitlist control
Trial: 23473396
Drug: Fibrinolysis with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolysis with bolus tenecteplase (half dose for patients ≥75 years), clopidogrel, and enoxaparin before transport to a PCI-capable hospital.
Trial: 21554679
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of salbutamol (15 μg kg ideal body weight‐1 hr‐1)
Trial: 17852392
Drug: High-dose NovaSil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose NovaSil (3.0 g NS day(-1))
Trial: 17852392
Drug: Low-dose NovaSil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose NovaSil (1.5 g NS day(-1))
Trial: 17852392
Drug: Placebo-control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-control (0 g NS day(-1))
Trial: 7814116
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment (ART) technique
Trial: 2735592
Drug: 20 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/kg normal saline infusion over 45 minutes
Trial: 2735592
Drug: 15 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL/kg normal saline infusion over one hour (after first infusion)
Trial: 2735592
Drug: 20 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/kg normal saline infusion over 45 minutes (Group B)
Trial: 2735592
Drug: 15 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL/kg normal saline infusion over three hours (after first infusion)
Trial: 31784345
Drug: Saury oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saury oil (12 g; 3.5 g of LCMUFA and 3.4 g of omega-3 FAs)
Trial: 31784345
Drug: Control oil
RxNorm normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oil (identical capsules with a mixture of sardine and olive oil; 4.9 g of shorter-chain MUFA oleate and 3 g of omega-3 FAs)
Trial: 27229178
Drug: Sitagliptin/metformin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin/metformin fixed-dose combination (Sita/Met)
Trial: 10688506
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg misoprostol orally every 4 hours to a maximum of three doses
Trial: 10688506
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin infusion according to the hospital protocol
Trial: 9352869
Drug: Lymphoblastoid IFN-alpha
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphoblastoid IFN-alpha (higher dosage and longer period)
Trial: 31423687
Drug: Chemical cardioversion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical cardioversion with procainamide infusion
Trial: 22692843
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg subcutaneous every 6 months)
Trial: 23597109
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day citalopram for 7 days
Trial: 20626147
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) combined with small dose of clozapine (50 mg/d to 100‐150 mg/d, 3 times a week for 8 weeks)
Trial: 20626147
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral administration of clozapine (50‐100 mg/d to 200‐500 mg/d, for 8 weeks)
Trial: 20626147
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) combined with small dose of clozapine
Trial: 19093056
Drug: Mandibular 2-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular 2-implant overdenture (IOD)
Trial: 16224525
Drug: Propofol and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and remifentanil (plasma concentration 4 microg/L)
Trial: 16224525
Drug: Propofol and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and remifentanil (plasma concentration 7 microg/L)
Trial: 16224525
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion using propofol with Marsh parameters
Trial: 10068928
Drug: UVA1 cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA1 cold light therapy
Trial: 10068928
Drug: Combined UVA-UVB
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined UVA-UVB therapy